AngioDynamics this week announced it received FDA 510(k) clearance for its AlphaVac F18 system to treat pulmonary embolism (PE). The expanded FDA indication allows for the use of AlphaVac F18 system for the treatment of PE. The new indication expands the device’s use in the non-surgical removal of thrombi or emboli from the venous vasculature. […]
AngioDynamics
AngioDynamics settles patent litigations with BD’s Bard
AngioDynamics entered into a settlement agreement with BD to resolve all patent litigations with Bard. Under terms of the agreement, BD will grant a license to AngioDynamics under certain of BD’s port patents. AngioDynamics will grant BD a license under certain of AngioDynamics’ catheter payments. AngioDynamics will also make a one-time payment of $7 million, […]
AngioDynamics sells PICC and Midline portfolios for $45M, discontinues sales of radiofrequency ablation devices
AngioDynamics recently announced the sale of its PICC and Midline product portfolios to Spectrum Vascular for up to $45 million in cash. The company PICC, Midline and tip location products contributed approximately $43.5 million in annual sales during AngioDynamics’ fiscal year 2023. The transaction consists of $34.5 million paid at closing, an earnout related to […]
AngioDynamics wins FDA breakthrough nod for AngioVac system
AngioDynamics (Nasdaq:ANGO) announced that it received FDA breakthrough device designation for its AngioVac system. The breakthrough nod includes proposed indications for the use of AngioVac in the non-surgical removal of vegetation from the right heart. AngioVac, an on-circuit aspiration system, uses a venous drainage cannula to remove thrombi or emboli during extracorporeal bypass. It achieves this […]
Merit Medical spends $132.5M on acquisitions to expand its offerings
AngioDynamics (Nasdaq:ANGO) announced that it completed the sale of its dialysis product portfolio to Merit Medical Systems. It was part of a series of product acquisitions worth $132.5 million that Merit (Nasdaq: MMSI) has announced. Latham, New York-based AngioDynamics sold its dialysis portfolio and the BioSentry product for $100 million in cash. The transaction includes […]
AngioDnamics stock rises on Street-beating Q2
AngioDynamics (Nasdaq:ANGO) shares are up today on second-quarter results that topped the consensus forecast. Shares of ANGO were up more than 11% at $15.24 apiece by the late morning. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up more than 7%. The Latham, New York–based peripheral […]
AngioDynamics slides on Q1 misses
AngioDynamics (Nasdaq:ANGO) shares took a hit today on first-quarter results that came up shy of the consensus forecast. Shares of ANGO dipped 12.6% at $18.84 apiece as the market opened today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 0.5%. The Latham, N.Y.–based peripheral artery […]
AngioDynamics rises on Q3 EPS beat
AngioDynamics (Nasdaq:ANGO) shares ticked up today on third-quarter results that were mixed compared to the consensus forecast. The Latham, N.Y.-based peripheral artery disease (PAD) treatment developer posted losses of nearly $5 million, or 13¢ per share, on sales of $74 million for the three months ended Feb. 28, 2022, for a 40% bottom-line slide on […]
AngioDynamics slides on mixed bag Q2
AngioDynamics (NSDQ:ANGO) shares took a hit today on second-quarter results that were mixed compared to the consensus forecast. The Latham, N.Y.-based peripheral artery disease (PAD) treatment developer posted losses of $8.4 million, or 21¢ per share, on sales of $78.3 million for the three months ended Nov. 30, 2021, nearly doubling its losses from the […]
AngioDynamics rises on Street-beating Q4 revenues
AngioDynamics (NSDQ:ANGO) shares ticked up this morning on fourth-quarter results that beat the consensus revenue forecast. The Latham, N.Y.-based peripheral artery disease (PAD) treatment developer posted losses of -$19.5 million, or -51¢ per share, on sales of $76.8 million for the three months ended May 31, 2021, for an 87.6% bottom-line gain on sales growth […]
AngioDynamics jumps on Street-beating Q1
AngioDynamics (NSDQ:ANGO) shares skyrocketed today on first-quarter results that topped the consensus forecast. Shares of ANGO were up 13.2% at $12.01 per share in mid-morning trading today. The Latham, N.Y.-based peripheral artery disease (PAD) treatment developer posted losses of -$4.3 million, or -11¢ per share, on sales of $70.2 million for the three months ended Aug. […]